These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35339102)

  • 1. Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum.
    Rosebraugh M; Stodtmann S; Liu W; Facheris MF
    Parkinsonism Relat Disord; 2022 Apr; 97():68-72. PubMed ID: 35339102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC-HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel.
    Savaryn JP; Smith RL; Rosebraugh M; Neenan M; Burton R; Marsh K; Wagner D
    Pharmacol Res Perspect; 2024 Apr; 12(2):e1190. PubMed ID: 38597598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion.
    Rosebraugh M; Liu W; Neenan M; Facheris MF
    J Parkinsons Dis; 2021; 11(4):1695-1702. PubMed ID: 34366380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
    Soileau MJ; Aldred J; Budur K; Fisseha N; Fung VS; Jeong A; Kimber TE; Klos K; Litvan I; O'Neill D; Robieson WZ; Spindler MA; Standaert DG; Talapala S; Vaou EO; Zheng H; Facheris MF; Hauser RA
    Lancet Neurol; 2022 Dec; 21(12):1099-1109. PubMed ID: 36402160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease.
    Rosebraugh M; Voight EA; Moussa EM; Jameel F; Lou X; Zhang GGZ; Mayer PT; Stolarik D; Carr RA; Enright BP; Liu W; Facheris MF; Kym PR
    Ann Neurol; 2021 Jul; 90(1):52-61. PubMed ID: 33772855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
    Aldred J; Freire-Alvarez E; Amelin AV; Antonini A; Bergmans B; Bergquist F; Bouchard M; Budur K; Carroll C; Chaudhuri KR; Criswell SR; Danielsen EH; Gandor F; Jia J; Kimber TE; Mochizuki H; Robieson WZ; Spiegel AM; Standaert DG; Talapala S; Facheris MF; Fung VSC
    Neurol Ther; 2023 Dec; 12(6):1937-1958. PubMed ID: 37632656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparability of Foslevodopa/Foscarbidopa Pharmacokinetics in Healthy Asian and White Participants.
    Rosebraugh M; Neenan M; Facheris M
    Clin Pharmacol Drug Dev; 2023 Apr; 12(4):407-415. PubMed ID: 36394144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
    Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
    Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease.
    Bergquist F; Ehrnebo M; Nyholm D; Johansson A; Lundin F; Odin P; Svenningsson P; Hansson F; Bring L; Eriksson E; Dizdar N
    Neurology; 2022 Sep; 99(10):e965-e976. PubMed ID: 35705502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets.
    Othman AA; Dutta S
    Br J Clin Pharmacol; 2014 Jul; 78(1):94-105. PubMed ID: 24433449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa infusion therapies for Parkinson disease.
    Dean MN; Standaert DG
    Curr Opin Neurol; 2024 Aug; 37(4):409-413. PubMed ID: 38780079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
    Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
    Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.
    Nyholm D; Odin P; Johansson A; Chatamra K; Locke C; Dutta S; Othman AA
    AAPS J; 2013 Apr; 15(2):316-23. PubMed ID: 23229334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and novel infusion therapies for patients with Parkinson's disease.
    Antonini A; D'Onofrio V; Guerra A
    J Neural Transm (Vienna); 2023 Nov; 130(11):1349-1358. PubMed ID: 37672049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation.
    Rosebraugh M; Kalluri HV; Liu W; Locke C; Sidhu D; Han JH; Benesh J
    Pharmacol Res Perspect; 2019 Apr; 7(2):e00473. PubMed ID: 30977301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
    Poewe W; Bergmann L; Kukreja P; Robieson WZ; Antonini A
    J Parkinsons Dis; 2019; 9(3):531-541. PubMed ID: 31282424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of Levodopa-Carbidopa Intestinal Gel Infusion Using Telemedicine (Video Communication System) Facilitates Efficient and Well-Accepted Home Titration in Patients with Advanced Parkinson's Disease.
    Willows T; Dizdar N; Nyholm D; Widner H; Grenholm P; Schmiauke U; Urbom A; Groth K; Larsson J; Permert J; Kjellander S
    J Parkinsons Dis; 2017; 7(4):719-728. PubMed ID: 28984615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.
    Slevin JT; Fernandez HH; Zadikoff C; Hall C; Eaton S; Dubow J; Chatamra K; Benesh J
    J Parkinsons Dis; 2015; 5(1):165-74. PubMed ID: 25588353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa.
    Kulisevsky J; Bejr-Kasem H; Martinez-Horta S; Horta-Barba A; Pascual-Sedano B; Campolongo A; Marín-Lahoz J; Aracil-Bolaños I; Pérez-Pérez J; Izquierdo-Barrionuevo C; de Fàbregues O; Puente V; Crespo-Cuevas A; Calopa M; Pagonabarraga J
    J Neurol; 2020 Nov; 267(11):3400-3410. PubMed ID: 32607644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infusion Therapies in the Treatment of Parkinson's Disease.
    van Laar T; Chaudhuri KR; Antonini A; Henriksen T; Trošt M
    J Parkinsons Dis; 2023; 13(5):641-657. PubMed ID: 37334617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.